The role of P-glycoprotein in drug resistance in multiple myeloma

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Multiple myeloma (MM) is a plasma cell malignancy impacting the bone marrow.
• Most MM patients initially respond to chemotherapy but develop drug resistance.
• Efflux transporters, particularly P-glycoprotein (P-gp), are key contributors to MM drug resistance.

Purpose of the Study:

• To review the role of P-glycoprotein in drug resistance in multiple myeloma.
• To highlight P-gp's involvement across various MM therapeutic classes.
• To emphasize the importance of understanding P-gp mechanisms for overcoming resistance.

Main Methods:

• Literature review focusing on P-glycoprotein (P-gp) and its role in multiple myeloma (MM).
• Analysis of studies investigating P-gp up-regulation in response to chemotherapeutic agents.
• Examination of P-gp's impact on intracellular drug accumulation and therapeutic efficacy.

Main Results:

• P-glycoprotein (P-gp) is frequently up-regulated by chemotherapeutic drugs in multiple myeloma (MM).
• This P-gp up-regulation reduces intracellular drug concentrations, diminishing treatment effectiveness.
• P-gp contributes to resistance against major MM drug classes, including proteasome inhibitors and anthracyclines.

Conclusions:

• P-glycoprotein is a significant factor in multiple myeloma drug resistance.
• Understanding P-gp's mechanism and developing inhibitors are crucial for enhancing MM treatment outcomes.
• Targeting P-gp may help overcome therapeutic resistance in multiple myeloma patients.